BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11

Benzinga · 2d ago
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.